Opinion
Video
Author(s):
Panelists discuss how, HPV+ head and neck cancer treatment typically follows NCCN guidelines: primary therapy includes surgery and/or chemoradiation based on staging. Immunotherapy like pembrolizumab is increasingly used, especially for recurrent/metastatic disease. Prognosis is generally better than HPV- cases.
Video content above is prompted by the following:
Targeted Therapies for NSCLC With Nonclassical EGFR Mutations Grow Increasingly Personalized
Next-Generation Sequencing Data Inform IO Treatment Sequencing in NSCLC
Neoadjuvant Botensilimab Plus Balstilimab Yields High MPR Rates in CRC
Comparable Survival Outcomes Observed With Atezolizumab/Bevacizumab vs Tremelimumab/Durvalumab in First-Line HCC
2 Commerce Drive
Cranbury, NJ 08512